Brentuximab vedotin, Polatozumab vedotin and Loncastuximab tesirine represent FDA-approved ADCs to treat different types of B cell lymphoma, targeting antigens such as CD30, which is expressed by activated B cells, CD79b, and CD19, present on all B cell types apart from pre-proB cells and mature plasma cells (32, 65–67). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.